Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer

Immune checkpoint inhibitors have been recently approved for cancer treatment. Nivolumab is a monoclonal antibody specific for programmed cell death-1 (PD-1) that modulates T-cell response. It was initially used for the treatment of malignant melanoma and then approved in other cancers, such as non-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Thyroid J
Main Authors: Palermo, Andrea, Napolitano, Andrea, Maggi, Daria, Naciu, Anda Mihaela, Tabacco, Gaia, Manfrini, Silvia, Crescenzi, Anna, Taffon, Chiara, Pantano, Francesco, Vincenzi, Bruno, Tonini, Guiseppe, Santini, Daniele
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2020
Assuntos:
Clinical Thyroidology / Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7265713/
https://ncbi.nlm.nih.gov/pubmed/32523892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000506107
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados